CompletedPhase 2NCT00002621

Interferon Alfa in Treating Children With HIV-Related Cancer

Studying Burkitt lymphoma

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Children's Oncology Group
Principal Investigator: V. M. Whitehead, MD, MD
Montreal Children's Hospital at McGill University Health Center
Intervention: recombinant interferon alfa(biological)
Enrollment: 8 enrolled
Eligibility: 21 years · All sexes
Timeline: 1994 – 2005

Study locations (10)

Via Christi Regional Medical Center, Wichita, Kansas, United States
MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, United States
Tomorrows Children's Institute, Hackensack, New Jersey, United States
Mission Saint Joseph's Health System, Asheville, North Carolina, United States
Medical City Dallas Hospital, Dallas, Texas, United States
San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas, United States
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
McGill University Health Center - Montreal Children's Hospital, Montreal, Quebec, Canada
University of Puerto Rico School of Medicine Medical Sciences Campus, San Juan, Puerto Rico
Clinique de Pediatrie, Geneva, Switzerland

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00002621 on ClinicalTrials.gov

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Burkitt lymphoma →

← Back to all trials